Real-world data on treatment persistence and measures to minimize cardiovascular risk in rheumatic patients using upadacitinib
Main finding · UPA persistenceResult — go to the resultHazard ratio 2.05 95% CI 1.2–3.49Authors' conclusion
In real-world clinical settings, UPA persistence is lower among RA patients who have received prior IL-6i treatment. Treatment strategies to avoid UPA in patients with CVR appear to be primarily driven by pivotal safety studies rather than regulatory guidance.
Study context
- Population
- RA and SpA patients initiating upadacitinib (UPA) or TNFi between January 2021 and December 2023
- Participants
- 306 participants
- Exposure
- UPA vs TNFi in RA and SpA
- UPAn = 153
- TNF inhibitors (TNFis)n = 153reference
- Outcome
- UPA treatment persistence and associated factors
Methodological detailsreal-world
- Real-world
Main finding
UPA persistence
Hazard ratio
2.05
95% CI 1.2–3.49
P = 0.008
By group
UPAvs TNFi in RA and SpA
HR 2.05 (95% CI 1.2–3.49); P = 0.008
As reported in the abstract
Observational data: associations, not effects.
Further findings
| Outcome | P value |
|---|---|
| Basal CVR at initiation, from February 2022Significantly lower basal CVR with UPA | P = 0.042 |
Disease activity indices · 3 years
- Significant improvements over 3 years
- P < 0.001
Original publication
Real-world data on treatment persistence and measures to minimize cardiovascular risk in rheumatic patients using upadacitinib. Rheumatology (Oxford). Published 22 October 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →